Feedstuffs is part of the divisionName Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

dairy cow black and white in field_venemama_iStock_Getty Images-847745536.jpg venemama/iStock/Getty Images

ImmuCell updates mastitis treatment approval status

Company continues regulatory review process for its nisin-based mastitis treatment for lactating dairy cows.

ImmuCell Corp. announced that it has received a response from the U.S. Food & Drug Administration to its first phased nisin drug substance submission of the Chemistry, Manufacturing & Controls (CMC) technical section for Re-Tain, the company’s novel treatment in development for subclinical mastitis in lactating dairy cows.

According to the announcement, under FDA’s phased submission process, Phase 1 concerns the nisin drug substance and Phase 2 concerns the Re-Tain drug product (formulated nisin filled in a syringe). As part of the phased submission process, FDA issued a "technical section incomplete letter" with various requests and queries in addition to referring to the fact that the second phased submission has yet to be submitted.

ImmuCell explained that this process allows a sponsor to respond to identified deficiencies from the first phased submission at the time of the second phased submission. The company said it expects to submit the second phased drug substance and drug product CMC technical section around the third quarter of 2020.

In addition to responding to comments raised by the FDA regarding the first phased submission, one of the key components of the second phased submission is demonstrating stability of the product over time using the commercial process and the commercial syringe, the company added.

“Having reviewed the comments from FDA, we see no road blocks on our path to FDA approval for Re-Tain,” ImmuCell president and chief executive officer Michael F. Brigham said. “We believe we can respond effectively to FDA’s comments without significant additional cost or time delays.”

Having previously achieved four different "technical section complete letters" from FDA, approval of the CMC technical section is the fifth and final significant step required before product sales can be initiated in the U.S., ImmuCell said.

ImmuCell's purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell markets First Defense, providing Immediate Immunity to newborn dairy and beef livestock, and is in the late stages of developing Re-Tain, a novel treatment for mastitis, the most significant cause of economic loss to the dairy industry.

Source: ImmuCell Corp., which is solely responsible for the information provided and is wholly owned by the source. Informa Business Media and all its subsidiaries are not responsible for any of the content contained in this information asset.
Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish